Outcome of the Board Meeting held on Friday, 29th May 2026
BROOKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Brooks Laboratories reported consolidated PAT of Rs 2,458.35 lakhs for FY26, a major turnaround from a loss of Rs 996.70 lakhs in FY25. Standalone revenue grew 3.9% to Rs 8,573.84 lakhs with PAT at Rs 580.50 lakhs (up 90%). The strong consolidated performance was driven by Brooks Steriscience (jointly controlled entity), which contributed Rs 1,877.85 lakhs to group profit through licensing income of Rs 5,996.64 lakhs. The company's diversification plans into non-pharma businesses were rejected by ROC (MGT-14 not approved), and the company will continue only in pharmaceutical operations. Prashant Rathi was appointed as CEO in addition to his CFO role. Cash and cash equivalents improved significantly to Rs 658.79 lakhs from Rs 4.34 lakhs. Auditors issued unmodified (clean) opinions on both standalone and consolidated results.
The stock may see positive sentiment due to the turnaround from loss to profit and strong cash position. However, investors should note that most profits come from a jointly controlled entity rather than core operations, and deferred tax assets remain unrecognized due to uncertainty over future taxable profits.